Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal ...

Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Discover a recent study that has provided valuable insights into the experiences of Latine patients living with moderate to ...

The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...

You can apply sunscreen to psoriasis plaques to prevent sunburn, but, if the plaques from psoriasis are inflamed or cracked ...

Published results showed “Latine” patients with psoriasis in the U.S. have unique experiences with their disease and ...

A doctor may prescribe injectable treatments, such as methotrexate, TNF-alpha inhibitors, or interleukin inhibitors, for moderate to severe psoriasis when other treatments don’t work.

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

In a new study, researchers have determined that a protein called NF-kB c-Rel can intensify the symptoms of psoriasis when activated by signals from the body's immune system. Understanding how 'c-Rel' ...

These findings may offer more personalized treatment and prevention recommendations for patients with psoriasis.

However, fungal infections are contagious, and psoriasis is not. The causes and treatment are also different. The autoimmune activity in psoriasis causes the rapid overgrowth of skin cells.